Global CAR T Cell Therapy Market and Clinical Trials Insight 2022

  • No. of Pages: 240
  • Publish Date: April-2017
  • Category: Pharmaceutical and Healthcare
Electronic Access - Single User License
$2400
CD-ROM Mail Delivery
$2800
Hard Copy Mail Delivery
$2800
Electronic Access - Multi-User License
$4800

“Global CAR T Cell Therapy Market and Clinical Trials Insight 2022” report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy.  As per report findings, the promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. Currently, there are 99 CAR T Cell based therapies in clinical pipeline and most of them belong to Phase-I and Phase-I/II clinical trials.  

 

In recent years, researchers have identified the chimeric antigen receptor as a potential target for molecular genetics to insert a new epitopes on the receptor region which allows a degree of control of the immune system. CAR T cell therapy satisfy the need to explore new and efficacious adoptive T cell therapy. The gene transfer technology could efficiently introduce the genes encoding CARs into the immune effector cells. The transferring of engineered T cells provides the specific antigen binding in a non-major histocompatibility complex.

 

The promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients.

 

The first commercial application of CAR T Cell based therapy for the treatment of Mantle- Non-Hodgkin's lymphoma is expected to be available from 2020. The anti-CD19 CAR T cell therapy axicabtagene ciloleucel (KTE-C19) is developed by KITE Pharma in collaboration with National Cancer Institute. Currently this therapy is in preregistration phase.

 

In future, the advancement of CAR T Cell therapy will be largely driven by academia and will require the support for the expensive early phase clinical trials which promise to cover the way for a new form of targeted, exportable immunotherapy for cancer patient. The manufacturing of CD19 CAR T cell therapy CTL019 is in a way which will modernize the process of using the therapy globally. The anticipation of regulatory and manufacturing issues before they arise and proactively addressing the concerns helps to accelerate the process of bringing this promising therapeutic approach to more patients in future.

 

 

“Global CAR T Cell Therapy Market and Clinical Trials Insight 2022” report highlights:

 

  • CAR T Cell Therapies Delivery Pipeline and Mechanism of Action
  • Global CAR T Cell Therapy Clinical Trials for Cancer Treatment
  • Global CAR T Cell Therapies Clinical Pipeline by Company, Indication and Phase
  • Global CAR T Cell Therapies Clinical Pipeline: 99 Therapies
  • CAR T Cell Therapies in Highest Phase:  Preregistration
  • Majority of  CAR T Cell Therapies in Phase-I/II Trials: 16 Therapies
  • Global Market Scenario of CAR T Cell Therapy
  • Global CAR T Cell Therapy Market Future Prospects

Need custom market research solution? We can help you with that too.